Tenax Therapeutics

Tenax Therapeutics

Pharmaceuticals
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

$64.7M

Market Cap • 11/17/2026

1967

(59 years)

Founded

1995

(31 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,6

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,4

EPS

1,4

Market Cap

Market Cap

64,7M

EV

-49,1M

EV/Revenue

—

EV/EBITDA

0,7

EV/EBIT

0,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-98,5%

Total Yield

-98,5%

Payout

0%

Retained Earnings

-417,7M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0%

ROE

64,2%

ROIC

—

Growth

CAGR Op. Income 5Y

16,5%

CAGR EPS 5Y

-76,7%

CAGR OCF 5Y

37,4%

Leverage

N.D./EBITDA

1,6

Debt/Equity

0%

Current Ratio

14

Quick Ratio

13,6

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium